The latest update is out from Inoviq Ltd ( (AU:IIQ) ).
INOVIQ Ltd has partnered with the Peter MacCallum Cancer Centre to validate its CAR-exosome therapy for treating solid tumors, specifically targeting Triple Negative Breast Cancer (TNBC). The collaboration involves in vitro and in vivo studies under a Master Service Agreement, with the aim of achieving significant milestones in the development of CAR-exosome therapy, potentially leading to Phase I clinical studies. This partnership is expected to enhance INOVIQ’s position in the cancer therapeutics industry by leveraging Peter Mac’s expertise in immunotherapy, thereby accelerating the development and potential market introduction of this innovative therapy.
More about Inoviq Ltd
INOVIQ Ltd is a biotechnology company specializing in next-generation diagnostics and therapeutics for cancer. The company has commercialized its EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test for bladder cancer. INOVIQ is advancing clinical-stage diagnostics for ovarian and breast cancers and early-stage exosome therapeutics for solid tumors.
YTD Price Performance: -21.36%
Average Trading Volume: 111,637
Technical Sentiment Signal: Buy
Current Market Cap: A$45.17M
For a thorough assessment of IIQ stock, go to TipRanks’ Stock Analysis page.